Is HHC Legal? Nine Countries and Four Mechanisms (2026)

HHC is sometimes described as a substance in a legal loophole. In nine countries for which we have measured status, no legal system leaves such a loophole; each closes it differently. In Poland, hexahydrocannabinol and its acetate have been on the list of psychotropic substances since May 5, 2023, so the question of legality has a short answer here, while the question of how it came about has a long one. You will also find here what HHC is chemically, how it is made from cannabidiol, how strongly it stimulates the CB1 receptor compared to THC, and what is known about its safety - which is less than the sales scale suggests.

Below there is no country-by-country review, because such a review explains nothing. Instead, there is a description of four mechanisms by which the law catches the same molecule, naming the countries for each.

KEY INFORMATION
- In Poland, HHC and HHC-O have been controlled substances since May 5, 2023 (Dz.U. 2023 item 744).
- The four mechanisms described below close the loophole differently: named list entry, general clause on molecular structure, psychoactive effect provision, and entry with reservation.
- HHC is produced from cannabidiol by hydrogenation, so it is not a natural cannabinoid.
- Immunological THC tests are not designed for HHC but cross-react with it and can give a positive result; a negative result does not exclude HHC intake.

How does the law catch a new hemp substance at all?

Drug law has four responses to a new substance, and all four are visible in this review. It can be included by name in a list, covered by a general clause describing the molecular structure, caught by a psychoactive effect provision, or entered with a reservation that shifts the boundary elsewhere.

The difference between them is practical, not theoretical. A named list works only after each new derivative is added, so the market reacts by changing the molecule. The general clause covers derivatives in advance, before anyone produces them.

The effect provision goes even further, as it does not ask about structure but about the effect on humans. The reservation in the entry itself can soften the whole construction, as we write about in Germany.

It is worth remembering one thing before reading the rest. None of the legal orders described here leaves HHC outside the law, although the effects differ, and in one case mere possession is not a crime.

The status of marijuana itself in these and other countries is collected separately in our marijuana legality map.

Which countries included HHC by name in their lists?

The most common solution is inclusion by name, and five of the nine countries described here did so. However, they differ in which list HHC was placed, which determines the effects, as the list decides the permitted purpose of the substance and who may legally handle it.

In Czechia, for years the European hub of trade in this substance, HHC is now in the strictest local list, alongside synthetic cannabinoids. The regulation narrowly defines this list: it includes substances allowed only for limited research, scientific, and very limited therapeutic purposes.

France banned HHC as one of the first in Europe, immediately together with derivatives. The list of narcotics included hexahydrocannabinol, its acetate, and hexahydrocannabiphorol, all in June 2023, and a year later another derivative that appeared on the market after the first ban was added.

In Slovakia, HHC is in the strictest group of the list, alongside hemp itself, and the list names derivatives and tetrahydrokanabidiol separately. In Denmark, the substance has been controlled since May 2023, and prosecutor guidelines treat synthetic and semi-synthetic cannabinoids together with hashish, with the same 10-gram threshold.

The strictest were Italy, contrary to intuition. The July 2023 decree placed this substance outside the hemp category, in the table of heavy substances, resulting in document suspension lasting up to a year instead of three months.

What is the general clause and why does it work better?

The general clause describes not the substance’s name but the molecular structure, and thus covers derivatives in advance, even those not yet on the market. The best example is Switzerland, which caught HHC twice: once by name and once by such a clause.

By name, the substance is in the list of raw materials and products with presumed effects similar to narcotics. This is a separate category from ordinary narcotics, including substances assumed to have such effects.

The strength of this solution lies in a separate entry dedicated to cannabinoids. It covers every substance structurally derived from a specific chemical skeleton, regardless of the degree of non-aromatic ring hydrogenation, substituted in three specified positions by any alkyl groups.

One phrase about the degree of hydrogenation closes the path that the market opened in other countries. A new derivative does not require addition to the list because it is covered in advance, so changing the molecule achieves nothing.

An exception was added to the clause, often misunderstood. The exclusion applies only to industrial and scientific uses, so private use remains controlled.

What does a country do that does not list HHC at all?

The third path is not to list the substance at all but still ban it. This is how the United Kingdom works, which is an exception in this review: HHC is not named in the drug law, yet its trade is prohibited.

The reason is technical and worth explaining. The local clause on cannabinoid derivatives has a narrow definition, covering tetrahydro derivatives and alkyl homologues of cannabinol, while HHC is a hexahydro derivative and thus not included.

We checked all four parts of the relevant annex to this law. The only name containing hexahydro there refers to a different, specific compound, not HHC itself.

However, the Psychoactive Substances Act 2016 closes the gap, built on the definition of effect rather than a list of names. It suffices that the substance stimulates or depresses the central nervous system and thereby changes the mental or emotional state of the user.

The effects here differ from those of a listed narcotic, and this is the essence of this mechanism. Manufacturing and supplying, holding the substance to pass it on, and import and export are punishable, but mere possession is not punishable except inside prison.

Why does the German entry not resolve the matter?

The fourth mechanism is an entry with reservation, best seen in Germany. Germany included it by name in the annex to the Narcotics Act, on the list of substances allowed for trade but not prescribable by doctors, and the reservation changes the effect of this entry.

However, the entry carries two exceptions that decide everything. The first covers hemp for medical or medical-scientific purposes under a separate law and is undisputed.

The second is unusual and breaks the whole construction. The non-synthetic form available for non-medical purposes is excluded from control, meaning the method of obtaining the substance, not its formula, decides.

We know the wording of this provision but do not know how German authorities treat commercial products made by hydrogenation of cannabidiol. Without this, it is impossible to say whether HHC from a store is legal in Germany or not.

We state this plainly instead of deciding a matter whose source does not decide. This is the only place in this review where the answer is “unknown,” and it is better to say so than falsely.

What does this mean for buyers and travelers?

The first conclusion is that the argument about a legal loophole does not work in any of the described countries. Even where HHC is not named, it is covered by the psychoactive effect provision, and where it is named, it usually appears on a stricter list than buyers expect.

The second conclusion concerns molecule changes. The market reacted to successive bans with derivatives, so countries using name lists had to tighten them, while those with a general clause did not need to do anything.

The third conclusion concerns Poland and is important because the national status is often described most incorrectly. HHC is neither a grey area nor a new psychoactive substance here: it is a psychotropic substance subject to the same criminal provisions of the anti-narcotics law as other substances on the list.

We do not provide the position of the entry in the Polish list, and this is a conscious decision. After the consolidated text of June 2024, two amendments to the same regulation entered, one of which moved the entry within the list; this is discussed below in the section on Polish HHC status. We do not provide the item number because it would require reading annexes of both amendments.

For travelers, the practical rule is the same as for dried flower. A product legally purchased elsewhere does not change status when crossing the border, and classification is decided by the list valid where you are.

What is HHC and where did it come from on the market?

HHC is a semi-synthetic cannabinoid obtained from hemp cannabidiol, not a compound extracted from the plant on a commercial scale. The compound itself is not new: its synthesis and ability to mimic cannabinoid effects were described eight decades ago during the search for the factor responsible for marijuana and hashish effects (Ujváry, Drug Testing and Analysis, 2024). It reached retail only in 2021.

It was preceded by two decades of turmoil in the illegal cannabinoid market, where successive cheap synthetic compounds with surprising structural diversity appeared; the novelty of recent years is semi-synthetic compounds obtained from hemp extracts by simple chemical transformations.

The reason for this delay is economic and regulatory. After legal changes in the United States, large-scale industrial hemp cultivation began, and cannabidiol from these crops changed from a target product to a cheap substrate for further chemical transformations. This route brought delta-8-THC, delta-10-THC, and HHC to the market in succession (Geci et al., Cannabis and Cannabinoid Research, 2023).

The spread of this market across Europe is documented. By early 2024, HHC presence was confirmed in 24 European countries, mostly as gummies and other edibles, disposable vaporizers, and flowers and resins with low THC content (Persson et al., Drug Testing and Analysis, 2025). The authors place HHC alongside the appearance of Spice-type mixtures in 2008 and call it the first major change in the cannabis substitute market since then. We discuss that wave more in the article on synthetic cannabinoids.

How is HHC made and why is it not a natural cannabinoid?

It is made in a reactor in two stages from a plant raw material. First, cannabidiol undergoes cyclization, producing a mixture of delta-8-THC and delta-9-THC. Then this mixture undergoes catalytic hydrogenation, i.e., saturation of the double bond with hydrogen, yielding a mixture of two spatial isomers of HHC (Ujváry, Drug Testing and Analysis, 2024). The name hexahydro refers to saturation of the structure, not the number of components in the preparation.

This is why the term natural is misleading here. Cannabidiol, cannabigerol, and cannabinol are produced in the plant with enzyme involvement, in a spatially specific way. HHC results from a chemical transformation lacking such selectivity, producing a mixture of molecular isomers. Work on obtaining an active isomer predominance was described only by a group from Modena in 2023 (Russo et al., Scientific Reports, 2023). That work calls it by its name: semi-synthetic cannabidiol derivatives are added to hemp products to circumvent legal restrictions.

A separate issue is that cannabidiol can convert into psychoactive compounds outside the reactor. A review of data indicates that in acidic environments cannabidiol decomposes into psychoactive products, but most studies do not confirm such transformation in humans. The authors conclude on storage stability, not effects (Golombek et al., Toxics, 2020).

How does HHC differ from THC and CBD?

HHC shares the chemical skeleton and CB1 receptor action with THC, and only the starting material with CBD. The practical difference is legal: THC and HHC are controlled substances, cannabidiol is not. The table below organizes these three compounds.

The last row often surprises readers. After HHC appeared in Sweden, the rate of false-positive THC screening tests in saliva and its metabolite in urine rose from below 2% to over 10%, and spiking experiments confirmed that cross-reactivity of antibodies with HHC is responsible (Helander et al., Scandinavian Journal of Clinical and Laboratory Investigation, 2024). If you are interested in how the receptors these compounds use work, we described it separately in the article on CB1 and CB2 receptors.

How do the 9R and 9S epimers differ and how strongly do they stimulate the CB1 receptor?

They differ in the arrangement of one group in the molecule, resulting in different potency. Hydrogenation yields a mixture of isomers labeled 9R and 9S. Preclinical studies indicate that the 9R isomer has properties close to THC (Ujváry, Drug Testing and Analysis, 2024). The ratio depends on synthesis conditions, so two products with the same declared HHC content may act differently.

Potency was measured in lab conditions on cells with human CB1 receptor. Both HHC isomers and derivatives were tested for potency and efficacy, using the synthetic cannabinoid JWH-018 known from Spice mixtures as a reference (Persson et al., Drug Testing and Analysis, 2025).

The authors draw two conclusions. First, the tested compounds mimic cannabinoids except for acetates. Second, acetates likely act as precursors, substances converted in the body to the active form, complicating effect prediction from lab tests alone.

The table also shows a discrepancy important for buyers. Potency of individual isomers differs severalfold, yet the list covers them together, as it does not distinguish epimers.

Is HHC legal in Poland?

No. HHC is a controlled substance in Poland and has been continuously since 2023. It was added to the list maintained by the Minister of Health together with HHC-O by regulation of April 17, 2023, effective May 5, 2023 (Dz.U. 2023 item 744).

The Minister of Health regulation of July 7, 2026, effective July 28, 2026, changed the position of HHC in this list (Dz.U. 2026 item 934). This is an internal move within the list, not removal of control.

This must be said plainly because Polish texts on HHC circulate the signature Dz.U. 2023 item 1232 as the basis for the ban. That signature belongs to the Ministry of National Defense regulation on foreign trips of professional soldiers. We checked this in the ELI register and provide it here because a wrong signature in legal texts is more dangerous than none: it looks like evidence.

Derivatives are also controlled. HHC-O has been listed since the same day as HHC. Hexahydrocannabiphorol, known as HHC-P, was added to the list of new psychoactive substances by regulation effective May 22, 2025 (Dz.U. 2025 item 598), together with delta-9-tetrahydrocannabiphorol. The legal status described in this article was established as of August 10, 2026, based on reading acts in the ELI register, not secondary sources.

It is useful to know the rhythm of these changes. The July 2026 regulation implements the European Commission delegated directive of October 14, 2025, amending the Council Framework Decision annex on including new psychoactive substances in the narcotic definition, and was notified to the Commission beforehand. The national list keeps pace with EU findings and changes several times a year. The practical conclusion for the reader is simple: the date of the legality statement is as important as the statement itself, and a text two years old may describe a state that no longer exists.

What are the penalties for possession and sale of HHC?

Criminal liability under the anti-narcotics law, with severity depending on the act and quantity. Possession of narcotics or psychotropic substances contrary to the law is punishable by up to 3 years imprisonment, and for significant quantities from 1 to 10 years.

Minor offenses have a separate, milder range: fine, restriction of liberty, or up to 1 year imprisonment (art. 62 of the law, consolidated text Dz.U. 2023 item 1939).

The law provides one relief valve. If the act involves a small amount for personal use, proceedings may be discontinued before investigation or inquiry if punishment would be pointless due to circumstances and social harm degree (art. 62a). This is a possibility, not a guarantee, assessed by prosecutor or court.

Trade is treated more severely. Introducing narcotics, psychotropic substances, or new psychoactive substances into circulation contrary to the law is punishable by fine and imprisonment from 6 months to 8 years, and for significant quantities from 2 to 12 years (art. 56). Manufacturing, processing, or altering is punishable by up to 3 years, and if involving significant quantities or for financial gain, by at least 3 years imprisonment (art. 53). Purchase date does not affect possession assessment after the ban effective date.

Do THC tests detect HHC?

Partially and not all. The same team that developed a method for detecting both HHC isomers in blood tested cross-reactivity of six compounds in five immunological screening tests for serum, urine, and saliva. Urine strip tests and ELISA serum tests were useful for detecting HHC, while saliva tests performed worse.

HHC analogues and hydrogenated cannabidiol showed no cross-reactivity in any tested tests (Höfert et al., Drug Testing and Analysis, 2024). We discuss hydrogenated cannabidiol separately in the article on H4CBD.

The same work provides first data on the phenomenon scale in traffic. Among 321 serum and plasma samples collected during roadside checks in western Saxony from drivers suspected of cannabis use, both HHC isomers were detected in 17 samples, i.e., 5.3%. This rate concerns a preselected group, not all drivers. The average 9R to 9S ratio was 1.99, with concentrations up to 35.35 ng/mL for 9R (Schirmer et al., European Journal of Mass Spectrometry, 2023). The human metabolism of HHC differs from THC. In a study with two volunteers who inhaled and ingested HHC, main metabolites detected in urine differed from delta-9-THC metabolites. The 9S isomer appeared in urine after both routes, while the more psychoactive 9R only after inhalation. The practical conclusion is inconvenient for both sides: a negative screening test does not prove no HHC intake. A 2024 literature review notes lack of rapid immunochemical methods for detecting HHC and its metabolites in urine, so detectability depends on the test used by a specific lab, not substance properties.

What is known about HHC safety in humans?

Much less than the product’s market presence suggests. A review summarizing HHC chemistry, analytics, and pharmacology states that human pharmacology, including metabolism, awaits study, while animal metabolism is partially known (Ujváry, Drug Testing and Analysis, 2024). This sentence comes from a literature review, not vendor material.

The second unknown is how often HHC is analyzed at all. The Modena group notes that knowledge about HHC, its pharmacological properties, and prevalence is limited because routine toxicological analyses usually do not include it (Russo et al., Scientific Reports, 2023). The substance may be present in samples but remain unreported.

What does this mean for risk assessment? The 9R isomer stimulates CB1 as a partial agonist, the same mechanism by which THC causes short-term memory impairment, reaction time lengthening, coordination disorders, and increased heart rate. The difference is that THC has dozens of human studies, while HHC has almost none. This is not an argument for safety but a description of a gap: a psychoactive substance entered the market before its effects were studied.

Laboratory study authors say this plainly. Data on semi-synthetic cannabinoids’ pharmacology are needed to understand their effects, assess health risks, and plan public health responses, and current data are sparse (Persson et al., Drug Testing and Analysis, 2025). Their own study concerned cultured cells, not humans, and this limitation cannot be bypassed by interpretation.

What are HHC-O and HHC-P and are they riskier?

These are HHC derivatives that appeared after it and have different action profiles. HHC-O is HHC acetate, a molecule with an attached acetate group. HHC-P, hexahydrocannabiphorol, has an extended side chain. Both substances are listed alongside HHC as further semi-synthetic cannabinoids appearing on the cannabis substitute market (Persson et al., Drug Testing and Analysis, 2025).

Studies on cells with human CB1 receptor showed that the active HHC-P isomer stimulates the receptor more strongly than the active HHC isomer: its potency was twice lower than JWH-018, while HHC was five times lower. Acetates behaved differently. The active HHC-O isomer stimulated the receptor even less, and the 9S isomer did not stimulate it at all, explained by the authors as acetates likely acting as precursors converted in the body.

From the user’s perspective, this means the worst possible arrangement. The product may contain a compound stronger than HHC or one whose effects cannot be predicted from lab tests, while the label uses a letter abbreviation. In Poland, HHC-O has been listed since May 5, 2023, and HHC-P since May 22, 2025, so neither derivative is a legal HHC substitute; both are compared in the HHC, HHC-O, and THCP legality table. The sequence of events illustrates the whole market mechanism: a derivative appears on sale, is listed, and then replaced by another molecule with even less documentation.

Does HHC get into products described as hemp?

Yes, and this is the main reason the topic concerns even those who do not seek HHC. The Modena group describes the mechanism bluntly: to circumvent legal restrictions, semi-synthetic cannabidiol derivatives producing effects similar to delta-9-THC are added to hemp products, which are openly sold in stores and online (Russo et al., Scientific Reports, 2023).

The forms in which HHC was found in Europe are exactly the same as those sold as industrial hemp products: gummies and other edibles, disposable vaporizers, and flowers and resins with low THC content. Buyers cannot distinguish them by appearance or smell, and the packaging description is often the only source of composition information.

This is why analytical methods matter. The Modena study used a rapid chromatographic method with UV detector and high-resolution mass spectrometer, allowing identification of up to ten main phytocannabinoids and both HHC isomers simultaneously in commercial hemp samples. Before such methods were used, HHC presence could simply be overlooked.

For Polish readers, the consequence is primarily legal. Possession of a controlled substance is a crime regardless of whether the buyer knew what the product contained. Risk is reduced by buying from sources presenting batch testing by external labs and avoiding products labeled with letter abbreviations whose meaning the seller cannot explain.

Why does the composition of HHC products remain unknown?

Because chemical transformations conducted outside pharmaceutical supervision yield not a single compound but a mixture. A review dedicated to delta-8-THC products from hemp cannabidiol describes this phenomenon in detail: the authors compiled documented by-products of acidic cannabidiol cyclization and emphasize that except for delta-8-THC itself, compounds in these mixtures have not undergone any toxicological evaluation in humans (Geci et al., Cannabis and Cannabinoid Research, 2023).

The same work assesses quality control in this emerging branch as completely insufficient and links it to a separate health problem: vaping products with uncertain composition fit into a wave of lung injuries associated with e-cigarettes, with mortality approaching 2% in California. The first synthesis stage of HHC is the same stage described in this review.

The third element is the document the seller uses to reassure the buyer. A certificate of analysis attached to a grey market product has no verifiable value: it cannot be checked whether it comes from testing that batch or whether the lab even exists. The method for determining both HHC isomers alongside main phytocannabinoids, described in the previous section, was developed in a scientific center and is not available to consumers.

The delta-8-THC review authors state they probably compiled the first complete list of documented by-products of this transformation and summarize the situation in one sentence: consumers take products labeled inconsistently with composition, containing compounds never tested for toxicity. The label in this market branch is thus a sales element, not composition information.

What is known about cannabinoids from industrial hemp?

That they are not controlled and data about them come from different types of studies. The Minister of Health lists name substances, and neither cannabidiol nor cannabigerol appear there even once, so neither is a controlled substance in Poland.

Industrial hemp plants have a total delta-9-THC and tetrahydrocannabinolic acid content in flowering tops not exceeding 0.3% dry weight, rounded to one decimal place (art. 4 point 5 of the anti-narcotics law).

Knowledge about cannabigerol is mainly based on user reports. The first survey among users of preparations with this cannabinoid included 127 participants. The most common reasons for use were anxiety (51.2%), chronic pain (40.9%), depression (33.1%), and insomnia and sleep disorders (30.7%). 44% reported no adverse effects; among reported ones, dry mouth (16.5%) and drowsiness (15%) dominated. Withdrawal symptoms were not reported by 84.3% (Russo et al., Cannabis and Cannabinoid Research, 2022). The authors conclude that preparations with cannabigerol dominance should be tested in randomized trials, as they have not been so far.

Cannabidiol has better documentation but is not neutral. A clinical data review lists fatigue, diarrhea, and appetite and weight changes as the most common adverse effects (Iffland and Grotenhermen, Cannabis and Cannabinoid Research, 2017), and the EFSA panel states that cannabidiol safety cannot be established for people under 25, pregnant and breastfeeding women, and those taking medications (EFSA Panel NDA, EFSA Journal, 2026). Legality is thus not the same as health neutrality. Hemp oils are collected in the oils category, and legal vaporizer raw material in the dried flower category.

What to do if someone took HHC and feels unwell?

For acute symptoms, call for help rather than wait for them to pass. Strong heart rate increase, chest pain, shortness of breath, anxiety attack with loss of contact with surroundings, or fainting are reasons to call 112 or go to the emergency room. Medical staff should be informed of the substance name, form taken, and time of intake.

Information about the substance itself is diagnostically important because routine screening may not detect HHC, and HHC metabolites differ from THC metabolites. Hiding this information from the doctor does not protect the patient but hinders diagnosis.

Milder symptoms usually require calm, quiet surroundings, hydration, and presence of another person. Do not combine psychoactive substances with alcohol or sedatives, as central nervous system depressant effects add up. After the incident, consult a family doctor or addiction specialist. Data on HHC behavior in humans are so sparse that no symptom list here should be treated as exhaustive. Driving is a separate matter. Since the 9R isomer stimulates CB1 like THC, impaired driving ability must be assumed, and blood tests of drivers in Saxony show HHC actually appears in roadside samples.

Frequently Asked Questions

Is HHC legal in Europe?

In none of the nine countries reviewed here is HHC outside the law. Five included it by name in their lists, Switzerland covered it with a general clause, the United Kingdom with a psychoactive effect provision, and Germany with an entry with reservation.

Is HHC legal in Poland?

No. HHC is a psychotropic substance in Poland and is subject to the same criminal provisions of the anti-narcotics law as other substances on the list. It is neither a grey area nor a new psychoactive substance.

Why did Czech shops sell HHC?

Today they do not operate in a legal loophole but outside the law. The substance was placed in the strictest Czech list, that of synthetic cannabinoids, where only narrowly defined research and very limited therapeutic uses remain legal.

What is the general clause in the Swiss list?

A description of the molecular structure instead of its name. It covers every substance derived from a specific chemical skeleton regardless of the degree of hydrogenation, so a new derivative is covered in advance without being added to the list.

Where is possession of HHC not a crime?

In the United Kingdom, outside prison grounds. Manufacturing and supplying, holding the substance to pass it to someone, as well as import and export remain punishable there.

Is HHC legal in Germany?

We do not decide this. The entry includes HHC but excludes the non-synthetic form available for non-medical purposes, and we have not determined how German authorities classify products made by hydrogenation of cannabidiol.

Which countries treat HHC more harshly than marijuana?

The Italian decree classified HHC as a heavy substance, excluding the hemp category, resulting in document suspension lasting up to a year instead of three months. Czechia and Slovakia placed it in their strictest lists.

Sources

This article is for informational and educational purposes and does not constitute legal advice. The legal status described applies as of the publication date: cannabis regulations may change. Consult a lawyer or current legal acts before making decisions.

Author: Michał Waluk · Published: 2026-05-11 · Updated: 2026-09-22